Scancell Share Discussion Threads

[inanaco] 19/9/2023 10:13

if you then add in the value of EIS and ISA schemes

the company and shareholders gain

but the ISA scheme is capital growth ..............

you have to find the right shares that are going to give that

its not

VAL


atb

[inanaco] 19/9/2023 10:09

phoenix

Scancell gets enormous tax breaks and ........ if and when it goes commercial it pays a lower corp tax rate



if you add up the tax credits they are millions


its not the GOV that is the issue its the idiot investors short term thinking

probably because they are under researched they rarely understand valuations

prime example is Colin and HVO

[inanaco] 19/9/2023 10:01

"" Based on the fact the traders are the ones who have made money over the last 12 years """

i am amazed you know that colin ... ?

i seem to recall most top ups by LTH are in the dips .............

indeed i topped up 500,000 below 8p

you should spend less time discussing "made up garbage" and more time researching the difference between the valuation

of HVO v FTSE 100 company


and explain to me how HVO sells at a higher multiple .............


maybe lozan is invested

[phoenixs] 19/9/2023 09:57

Chillpill, …as if that has not been going on for years now. There is little incentive to take risk. No decent tax breaks and certainly a lack of government support for innovation and development. That is why companies either move to the USA or are bought by companies in the USA.
Re Scancell, validation is the name of the game at which point who knows the price but I believe that it will be bought out during the next 18 months. Hopefully at a good price for shareholders.

[ivyspivey] 19/9/2023 09:54

Morning and what very good news announced today for both patients and investors and do not underestimate the significance of todays news.
Obviously with likes of Captain Hindsight if I had along with others had held on to the ones we bought 2 weeks ago we would be showing a lot more profit.
Based on the fact the traders are the ones who have made money over the last 12 years part of most of our plans was to trade the extra ones we bought whilst keeping a core holding.
So to me a 50% profit is very nice and yes you may be lucky but greed has been the downfall of many in AIM.
So well done to LTH who held and those that too the profit as there is no one way but what works for you and remember there is a whole wide market out there for those brave enough to swim in more than one pool

[chillpill] 19/9/2023 09:42

The AIM market and brokers will continue to contract.
The mindset to business and investment in the UK worsens by the year.

[inanaco] 19/9/2023 09:38

Colin from accounts states .....

you learn from your losses ........


i guess that includes selling to early ...

he really does clock up the statistics does our Colin

[inanaco] 19/9/2023 09:37

he would love to be a Happy seller ........ but Britain's Best investor "lozan" had already blown his capital buying Logs ...... shares ... way to risky


hedging against a cold winter

[markingtime] 19/9/2023 09:34

What do you care? You were a happy seller yesterday at 12.50p......:-)

[babbler] 19/9/2023 09:30

UK market is pretty dead. Dore. Awful. Only stocks that seem to do well are dogs and dead shares that get gamblers in pumping them... not all shares but quite a lot of them.Not really surprising.a lot of shares delisting or moving to USA.

[babbler] 19/9/2023 09:28

See other thread.

[18bt] 19/9/2023 09:26

Amazed no comment so far on today’s announcement. V encouraging.

[inanaco] 19/9/2023 09:23

the uk market sold Arm to the japanese who sold it to the Americans

who lost ?

British investors

short sighted, useless at research, and worse constant negative outlook

in fact the ultimate UK investor badge must go to

Lozan

[babbler] 19/9/2023 09:19

In USA this would have bagged by now today.

[inanaco] 19/9/2023 09:10

SCIB1 never cured the mouse ............

Iscib1 did

[markingtime] 19/9/2023 09:08

Indeed it is still cheap. I expect a ten-fold rise over the next year from the present 16p.

[marcusl2] 19/9/2023 08:51

According to Trinity Delta, the study's success is even more impressive when compared to other treatments.

Usually, the best results seen in this type of advanced skin cancer are around a 48-58% success rate.

Scancell's study is now moving to the next phase, where it plans to treat 27 more patients.

The company also plans to test an enhanced version of the vaccine, which could potentially work for all skin cancer patients and is more potent.

Trinity Delta expects data from these new tests by the first half of 2024. It also noted that Scancell is likely to explore partnerships and other business deals, given the strength of these results.

The research currently values Scancell at £300.1 million, or 36.7 pence per share.

[chillpill] 19/9/2023 08:48

I was a shareholder in BB Biotech back in 1996 when US investors got excited and to it to a market cap of $2.5 billion (big enough for FTSE 100) and they were at the pre-clinical stage.

Let’s hope for some mainstream press coverage on this stunning (early) data.

[inanaco] 19/9/2023 08:47

"""In addition to SCIB1, Scancell expects significant results from its other programmes in 2024 including top-line Modi-1 CPI combination data and attractive out-licensing opportunities from the GlyMab® and AvidiMab® platforms."""

get ready for the next event

""""""""" top-line Modi-1 CPI combination data """"""


Synonyms of top line (adj.

excellent. exceptional. high-quality. marvelous. outstanding.

[miavoce] 19/9/2023 08:45

Zac Mir's forecast (a few weeks ago) of 20p by end Sept is looking very doable.

[marcusl2] 19/9/2023 08:39

Research house Trinity Delta said: "Although a small patient population, these highly impressive data from the SCOPE study effectively demonstrate the concept of using the SCIB vaccine in combination with CPIs.

"The strength of the results means the second stage of the study, treating a further 27 patients (bringing the total to 43), has a 90% probability of success.

"In parallel, a new patient cohort will examine the same CPI doublet in combination with iSCIB1+, which offers broader patient applicability and greater potency."

Professor Poulam Patel, the chief investigator, said: "These results if confirmed in a larger cohort, will significantly improve upon current treatment options. We are eager to proceed to the second stage of the study and will report additional data in due course."

[marcusl2] 19/9/2023 08:32

and that was not with doublet, only Keytruda!


Oct 22
Shares in Moderna were ticking upwards today after Merck & Co took up an option on a personalised RNA-based cancer vaccine with a payment of $250 million.

How much for the Immunobody platform and use of Avidimab?

[inanaco] 19/9/2023 08:29

advice

its so cheap ....... even at 37p trinity values

atb